A detailed history of Israel Englander (Millennium Management LLC) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Millennium Management LLC holds 107,500 shares of NBIX stock, worth $13.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
107,500
Previous 455,220 76.39%
Holding current value
$13.5 Million
Previous $62.8 Million 76.43%
% of portfolio
0.01%
Previous 0.03%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $35 Million - $38.3 Million
-267,737 Reduced 58.81%
187,483 $25.8 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $30.5 Million - $33.6 Million
-233,736 Reduced 33.93%
455,220 $62.8 Million
Q4 2023

Feb 14, 2024

SELL
$106.07 - $132.76 $17.1 Million - $21.4 Million
-161,302 Reduced 18.97%
688,956 $90.8 Million
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $25.2 Million - $29.6 Million
281,983 Added 49.62%
850,258 $80.2 Million
Q1 2023

May 15, 2023

SELL
$94.11 - $123.02 $25.6 Million - $33.5 Million
-272,065 Reduced 32.38%
568,275 $57.5 Million
Q4 2022

Feb 14, 2023

BUY
$106.72 - $127.06 $28.5 Million - $34 Million
267,284 Added 46.64%
840,340 $100 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $19.4 Million - $22.7 Million
210,383 Added 58.01%
573,056 $60.9 Million
Q2 2022

Aug 15, 2022

SELL
$75.79 - $100.07 $10.4 Million - $13.8 Million
-137,454 Reduced 27.48%
362,673 $35.4 Million
Q1 2022

May 16, 2022

SELL
$72.45 - $94.81 $4.41 Million - $5.77 Million
-60,870 Reduced 10.85%
500,127 $46.9 Million
Q4 2021

Feb 14, 2022

BUY
$79.65 - $106.22 $5.56 Million - $7.41 Million
69,753 Added 14.2%
560,997 $47.8 Million
Q3 2021

Nov 15, 2021

BUY
$86.18 - $99.03 $31.9 Million - $36.6 Million
369,733 Added 304.28%
491,244 $47.1 Million
Q2 2021

Aug 16, 2021

SELL
$89.43 - $102.27 $9.27 Million - $10.6 Million
-103,645 Reduced 46.03%
121,511 $11.8 Million
Q4 2020

Feb 16, 2021

BUY
$86.91 - $108.33 $15.9 Million - $19.8 Million
182,520 Added 428.09%
225,156 $21.6 Million
Q3 2020

Nov 16, 2020

SELL
$96.16 - $135.15 $1.59 Million - $2.23 Million
-16,514 Reduced 27.92%
42,636 $4.1 Million
Q2 2020

Aug 14, 2020

SELL
$85.09 - $130.36 $4.91 Million - $7.52 Million
-57,650 Reduced 49.36%
59,150 $7.22 Million
Q1 2020

May 14, 2020

SELL
$75.11 - $113.76 $20.2 Million - $30.6 Million
-269,258 Reduced 69.75%
116,800 $10.1 Million
Q4 2019

Feb 14, 2020

BUY
$86.8 - $118.57 $9.46 Million - $12.9 Million
109,006 Added 39.34%
386,058 $41.5 Million
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $6.15 Million - $7.44 Million
73,342 Added 36.0%
277,052 $25 Million
Q2 2019

Aug 15, 2019

SELL
$72.24 - $91.27 $36.9 Million - $46.7 Million
-511,295 Reduced 71.51%
203,710 $17.2 Million
Q2 2019

Aug 14, 2019

BUY
$72.24 - $91.27 $11.2 Million - $14.2 Million
155,057 Added 27.69%
715,005 $31.3 Million
Q1 2019

May 14, 2019

BUY
$69.31 - $91.53 $37.4 Million - $49.4 Million
539,208 Added 2599.85%
559,948 $49.3 Million
Q4 2018

Feb 14, 2019

SELL
$68.32 - $124.36 $23.1 Million - $42 Million
-337,795 Reduced 94.22%
20,740 $1.48 Million
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $32.8 Million - $41.7 Million
331,346 Added 1218.68%
358,535 $44.1 Million
Q2 2018

Aug 14, 2018

SELL
$75.3 - $105.99 $7.58 Million - $10.7 Million
-100,726 Reduced 78.74%
27,189 $2.67 Million
Q1 2018

May 15, 2018

SELL
$75.88 - $92.43 $30.9 Million - $37.6 Million
-406,651 Reduced 76.07%
127,915 $10.6 Million
Q4 2017

Feb 14, 2018

BUY
$58.53 - $77.59 $24.4 Million - $32.4 Million
417,661 Added 357.27%
534,566 $41.5 Million
Q3 2017

Nov 14, 2017

BUY
$47.97 - $61.28 $5.61 Million - $7.16 Million
116,905
116,905 $7.16 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.